Andy I. M. Hoepelman

16.0k citations

255 papers · 10.5k indexed · 2 hit papers · h-index 53

Epidemiology top 0.2%
Infectious Diseases top 0.2%
Virology top 0.5%
Immunology top 2%
Molecular Biology top 10%

Co-authors: Suzanne E. Geerlings Jan Jelrik Oosterheert Eelko Hak Roos E. Barth K. J. Gorter Guy E.H.M. Rutten Rob Schuurman François Schellevis
Topics: HIV/AIDS drug development and treatment (49 papers)HIV Research and Treatment (43 papers)HIV/AIDS Research and Interventions (42 papers)
Cited by: Virology Infectious Diseases Epidemiology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences The Lancet
Partner nations: Netherlands United States Germany

In The Last Decade

Andy I. M. Hoepelman

252 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune dysfunction in patients with diabetes mellitus (DM)

1999 943 citations Suzanne E. Geerlings, Andy I. M. Hoepelman FEMS Immunology & Medical Microbiology profile →
Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus

2005 743 citations Eelko Hak, Andy I. M. Hoepelman et al. Clinical Infectious Diseases profile →

Peers

Countries citing papers authored by Andy I. M. Hoepelman

Since Specialization

Citations

This map shows the geographic impact of Andy I. M. Hoepelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy I. M. Hoepelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy I. M. Hoepelman more than expected).

Fields of papers citing papers by Andy I. M. Hoepelman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy I. M. Hoepelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy I. M. Hoepelman. The network helps show where Andy I. M. Hoepelman may publish in the future.

Co-authorship network of co-authors of Andy I. M. Hoepelman

This figure shows the co-authorship network connecting the top 25 collaborators of Andy I. M. Hoepelman. A scholar is included among the top collaborators of Andy I. M. Hoepelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy I. M. Hoepelman. Andy I. M. Hoepelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selective decline of intact HIV reservoirs during the first decade of ART followed by stabilization in memory T cell subsets 2025 ·AIDS ·(unknown),(unknown),(unknown),(unknown),Lavina Gharu,Dorien de Jong,(unknown),(unknown),Kiki Tesselaar,Aridaman Pandit,Joop E. Arends,Sigrid A. Otto,(unknown),Andy I. M. Hoepelman,Rob J. de Boer,Jori Symons,José A. M. Borghans,Annemarie M. J. Wensing,Monique Nijhuis	1
2	Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen 2024 ·Viruses ·(unknown),(unknown),Wouter F.W. Bierman,Reinout van Crevel,Andy I. M. Hoepelman,Mark A. A. Claassen,Heidi Ammerlaan,Berend J. van Welzen,M.E.E. van Kasteren,S.F.L. van Lelyveld,Dorien de Jong,Kiki Tesselaar,Matthijs van Luin,Monique Nijhuis,Annemarie M. J. Wensing,(unknown)	2
3	Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study 2023 ·Journal of Medical Virology ·(unknown),(unknown),L. Marije Hofstra,Monique Nijhuis,Annelies Verbon,Tania Mudrikova,Annemarie M. J. Wensing,Andy I. M. Hoepelman,Berend J. van Welzen	3
4	No increased risk of mature B-cell non-Hodgkin lymphoma after Q fever detected: results from a 16-year ecological analysis of the Dutch population incorporating the 2007–2010 Q fever outbreak 2022 ·International Journal of Epidemiology ·Jesper M. Weehuizen,(unknown),(unknown),Wim van der Hoek,Marc J. M. Bonten,Andy I. M. Hoepelman,Chantal P. Bleeker‐Rovers,Peter C. Wever,Jan Jelrik Oosterheert	5
5	No Influence of Previous Coxiella burnetii Infection on ICU Admission and Mortality in Emergency Department Patients Infected with SARS-CoV-2 2022 ·Journal of Clinical Medicine ·Jesper M. Weehuizen,(unknown),Andy I. M. Hoepelman,Chantal P. Bleeker‐Rovers,Jan Jelrik Oosterheert,Peter C. Wever	1
6	An open‐label cluster‐randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID‐19 (ARCHAIC)—Protocol publication 2020 ·European Journal of Clinical Investigation ·Jesper M. Weehuizen,Andy I. M. Hoepelman	5
7	Coxiella burnetii in non-Hodgkin lymphoma tissue samples: Innocent until proven otherwise? 2018 ·Immunobiology ·(unknown),Mirjam H. A. Hermans,Peet Nooijen,A H E Herbers,Chantal P. Bleeker‐Rovers,Andy I. M. Hoepelman,Jan Jelrik Oosterheert,Peter C. Wever	8
8	Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection. 2017 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),Astrid M. Newsum,Cynthia K. Y. Ho,Janke Schinkel,Richard Molenkamp,Jan T. M. van der Meer,Joop E. Arends,Andy I. M. Hoepelman,A. M. J. Wensing,Peter D. Siersema,Karel J. van Erpecum,Greet J. Boland	2
9	Diagnostic, therapeutic and economic consequences of a positive urinary antigen test for Legionella spp. in patients admitted with community-acquired pneumonia: a 7-year retrospective evaluation 2013 ·Journal of Clinical Pathology ·(unknown),Labrinus van Manen,Andy I. M. Hoepelman,Steven Thijsen,Jan Jelrik Oosterheert	14
10	Human African trypanosomiasis: a review of non-endemic cases in the past 20 years 2011 ·International Journal of Infectious Diseases ·Stephanie J Migchelsen,Philippe Büscher,Andy I. M. Hoepelman,Henk D. F. H. Schallig,Emily R. Adams	41
11	Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus 2010 ·Gastroenterology ·T.E.M.S. de Vries-Sluijs,Jurriën G.P. Reijnders,Bettina E. Hansen,Hans L. Zaaijer,Jan M. Prins,Suzan D. Pas,Martin Schutten,Andy I. M. Hoepelman,Clemens Richter,Jan W. Mulder,Rob A. de Man,Harry L.A. Janssen,Marc van der Valk	85
12	Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines 2010 ·International Journal of Infectious Diseases ·(unknown),Roel Polak,Andy I. M. Hoepelman,Edgar Delgado,(unknown),(unknown)	55
13	Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia compared with the general Dutch population 2010 ·Clinical Microbiology and Infection ·Anke H. W. Bruns,Jan Jelrik Oosterheert,(unknown),Rachida el Moussaoui,Rolf H. H. Groenwold,Jan M. Prins,Andy I. M. Hoepelman	1
14	Pneumonia Recovery; Discrepancies in Perspectives of the Radiologist, Physician and Patient 2009 ·Journal of General Internal Medicine ·Anke H. W. Bruns,Jan Jelrik Oosterheert,Rachida el Moussaoui,Brent C. Opmeer,Andy I. M. Hoepelman,Jan M. Prins	39
15	Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa 2008 ·AIDS ·Roos E. Barth,Annemarie M. J. Wensing,Hugo A. Tempelman,(unknown),Rob Schuurman,Andy I. M. Hoepelman	52
16	Impact of Rapid Detection of Viral and Atypical Bacterial Pathogens by Real-Time Polymerase Chain Reaction for Patients with Lower Respiratory Tract Infection 2005 ·Clinical Infectious Diseases ·Jan Jelrik Oosterheert,Anton M. van Loon,Rob Schuurman,Andy I. M. Hoepelman,Eelko Hak,Steven Thijsen,G.D. Nossent,M. M. E. Schneider,(unknown),Marc J. M. Bonten	152
17	O -Acetylation of Cryptococcal Capsular Glucuronoxylomannan Is Essential for Interference with Neutrophil Migration 2004 ·The Journal of Immunology ·Pauline M. Ellerbroek,Dirk J. Lefeber,Richard van Veghel,Jelle Scharringa,Ellen C. Brouwer,Gerrit J. Gerwig,Guilhem Janbon,Andy I. M. Hoepelman,Frank E. J. Coenjaerts	50
18	Potent Inhibition of Neutrophil Migration by Cryptococcal Mannoprotein-4-Induced Desensitization 2001 ·The Journal of Immunology ·Frank E. J. Coenjaerts,Annemiek Walenkamp,Pauline N. M. Mwinzi,Jelle Scharringa,Huberta A. T. Dekker,Jos A. G. van Strijp,Robert Cherniak,Andy I. M. Hoepelman	36
19	Immune dysfunction in patients with diabetes mellitus (DM)breakdown → 1999 ·FEMS Immunology & Medical Microbiology ·Suzanne E. Geerlings,Andy I. M. Hoepelman	943
20	Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients 1995 ·FEMS Immunology & Medical Microbiology ·(unknown),Ger T. Rijkers,Piet C. Aerts,(unknown),Andy I. M. Hoepelman,Johannes van Dijk,Jan C.C. Borleffs	21

About Andy I. M. Hoepelman

Andy I. M. Hoepelman is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 255 papers that have together received 10.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (49 papers), HIV Research and Treatment (43 papers) and HIV/AIDS Research and Interventions (42 papers). The work is most often cited by research in Virology (1.3k citations), Infectious Diseases (4.1k citations) and Epidemiology (5.3k citations). Andy I. M. Hoepelman has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Suzanne E. Geerlings, Jan Jelrik Oosterheert, Eelko Hak, Roos E. Barth, K. J. Gorter, Guy E.H.M. Rutten, Rob Schuurman, François Schellevis, Marc J. M. Bonten and Jan C.C. Borleffs. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact